Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.
SB 1121 Contains Common Sense, Bipartisan Fix to Unintended Consequences of Data Privacy Bill
The Trump administration has launched a sweeping federal review on the use of fetal tissue that includes the cancellation of a contract between a supplier and researchers at the U.S. Food and Drug Administration.
For the first time in Europe, a pegylated G-CSF biosimilar pegfilgrastim will be available to patients for the treatment of neutropenia
Politicians might deny climate change, but disease-carrying insects and their pathogens aren’t—they’re exploiting it.
Making the jump from biotech to politics may not seem like a typical career progression. So, what is driving these executives into politics?
Recently, a few companies and government programs have decided to enact their own plans that they believe will help bring down the cost of new therapies. Pharmaceutical companies have begun asserting their positions on the topic.
Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.
Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.
Palantir Technologies announced today that it has been awarded a three-year, $7 million contract by the National Institutes of Health (NIH).